Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | CDC25B | P30305 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14414823 | 1.00 | TACR2 (0.47) | TACR2LGALS8SLC6A2LMNAPTPN1 | |
| SCHEMBL970383 | 0.91 | LGALS8 (0.54) | LGALS8SLC6A2LMNAPTPN1ALDH1A1 | |
| SCHEMBL970381 | 0.91 | LGALS8 (0.54) | LGALS8SLC6A2LMNAPTPN1ALDH1A1 | |
| SCHEMBL6896371 | 0.91 | LGALS8 (0.52) | TACR2LGALS8SLC6A2PTPN1CYP2D6 | |
| SCHEMBL12917696 | 0.91 | LGALS8 (0.54) | LGALS8SLC6A2LMNAPTPN1ALDH1A1 | |
| SCHEMBL9798087 | 0.91 | LMNA (0.48) | TACR2LGALS8SLC6A2LMNAPTPN1 | |
| SCHEMBL9798078 | 0.91 | LMNA (0.48) | TACR2LGALS8SLC6A2LMNAPTPN1 | |
| SCHEMBL25084211 | 0.90 | NT5E (0.48) | TACR2LGALS8SLC6A2LMNAPTPN1 | |
| SCHEMBL14414816 | 0.88 | NT5E (0.57) | TACR2LMNAPTPN1CDC25BNT5E | |
| SCHEMBL9778036 | 0.88 | LGALS8 (0.53) | LGALS8SLC6A2POLBLGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225246-A1 | O-acetyl-ADP-ribose non-hydrolyzable analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225246-A1 | O-acetyl-ADP-ribose non-hydrolyzable analogs | PARP1, TIPARP, CD38 | TACR2 4735/4885LGALS8 1704/4885SLC6A2 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.